etoposide has been researched along with bay 1000394 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lienau, P; Lücking, U; Mumberg, D; Schatz, C; Siemeister, G; Steinke, W; Wengner, AM; Ziegelbauer, K | 1 |
| Albert, I; Barlesi, F; Bidoli, P; Cadranel, J; Chung, J; Drews, U; Fritsch, A; Govindan, R; Horn, L; Juhász, E; Kowalski, D; Novello, S; Reck, M; Robinet, G; Wagner, A | 1 |
| Li, Z; Lu, S | 1 |
1 trial(s) available for etoposide and bay 1000394
| Article | Year |
|---|---|
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Small Cell Lung Carcinoma; Sulfoxides | 2019 |
2 other study(ies) available for etoposide and bay 1000394
| Article | Year |
|---|---|
BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cisplatin; Cyclin-Dependent Kinases; Etoposide; Female; Humans; Mice; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Rats; Retinoblastoma Protein; Sulfoxides; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Rethinking Our Approach of Combining Novel Agents With Standard Chemotherapy in Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Pyrimidines; Small Cell Lung Carcinoma; Sulfoxides | 2019 |